Atlas Trials

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

Clinical trial NCT06531499 · RECRUITING

Trial details

NCT number
NCT06531499
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Metastatic Castration-Resistant Prostate Cancer
Start date
2024-11-11
Primary completion
2028-11-24
Enrollment
106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.